Clinical trial
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
NCT02625480 is registered in ClinicalTrials.gov with Kite, A Gilead Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
- Lead sponsor
- Kite, A Gilead Company
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 1, 2016
- Completion date
- March 25, 2026
- Enrollment
- 95 (actual)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed/refractory b-cell non-hodgkin lymphoma, relapsed/refractory b-precursor acute lymphoblastic leukemia